Company profile
Paradromics
Building the industry-leading brain-computer interface (BCI) platform.
- Industry
- Biotechnology Research
- Employees
- 119
- Headquarters
- Austin, Texas
- Founded
- 2015
- LinkedIn followers
- 32,574
- Office locations
- 2
Paradromics company summary
Paradromics is a company in the Biotechnology Research industry, headquartered in Austin, Texas, founded in 2015. On LinkedIn the company has around 119 employees and 32,574 followers. The company lists 2 office locations. Its listed specialties include Neural Interfaces, Brain Computer Interface, Assistive Communication Devices, BCI, Neuroscience.
What technology does Paradromics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Paradromics
ENABLING NEUROTECHNOLOGY Paradromics builds brain-computer interface (BCI) technologies for seamless human-technology integration, designed to restore and enhance human capabilities. By capturing brain activity at the resolution of individual neurons, our high-data-rate platform creates a foundation for the most advanced BCI applications. With each new application, we will create human capabilities that transcend disabilities, and eventually, biology itself. THE MISSION Data-driven BCI-based technologies for brain health Our technology will help millions with unmet medical needs suffering from paralysis and movement disorders to chronic pain, addiction, depression and other mental health conditions. ABOUT Matt Angle Ph.D. (CEO) founded Paradromics to build a high-data-rate BCI platform capable of addressing critical unmet clinical needs. With early funding from the NIH and DARPA, the company developed its core neurotechnology and, by 2019, shifted focus to its first product: the Connexus® BCI. Connexus is designed to restore communication through text, synthesized speech, and computer control for people with severe motor impairments, including those caused by ALS, stroke, or spinal cord injury. Backed by two FDA Breakthrough Device Designations and a successful first-in-human recording in May 2025, Paradromics achieved its first human implantation of the Connexus BCI as part of the FDA-approved Connect-One study in June 2026, marking a major milestone toward delivering its first product to people living with severe motor impairment.
Specialties
Where is Paradromics located?
Paradromics lists 2 office locations.
Compare companies similar to Paradromics
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Paradromics paradromics.com | Biotechnology Research | 119 | 2015 | Austin, Texas |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Paradromics
What does Paradromics do?
ENABLING NEUROTECHNOLOGY Paradromics builds brain-computer interface (BCI) technologies for seamless human-technology integration, designed to restore and enhance human capabilities. By capturing brain activity at the resolution of individual neurons, our high-data-rate platform creates a foundation for the most advanced BCI applications. With each new application, we will create human capabilities that transcend disabilities, and eventually, biology itself. THE MISSION Data-driven BCI-based technologies for brain health Our technology will help millions with unmet medical needs suffering from paralysis and movement disorders to chronic pain, addiction, depression and other mental health conditions. ABOUT Matt Angle Ph.D. (CEO) founded Paradromics to build a high-data-rate BCI platform capable of addressing critical unmet clinical needs. With early funding from the NIH and DARPA, the company developed its core neurotechnology and, by 2019, shifted focus to its first product: the Connexus® BCI. Connexus is designed to restore communication through text, synthesized speech, and computer control for people with severe motor impairments, including those caused by ALS, stroke, or spinal cord injury. Backed by two FDA Breakthrough Device Designations and a successful first-in-human recording in May 2025, Paradromics achieved its first human implantation of the Connexus BCI as part of the FDA-approved Connect-One study in June 2026, marking a major milestone toward delivering its first product to people living with severe motor impairment.
How many employees does Paradromics have?
Paradromics has around 119 employees on LinkedIn.
Where is Paradromics headquartered?
Paradromics is headquartered in Austin, Texas.
Where does Paradromics have offices?
Paradromics lists 2 office locations, including Austin, Texas, US; Oakland, California, US.
When was Paradromics founded?
Paradromics was founded in 2015.
Build a lead list from companies like Paradromics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.